GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (OSTO:MODTX) » Definitions » Gross-Profit-to-Asset %

Modus Therapeutics Holding AB (OSTO:MODTX) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Modus Therapeutics Holding AB's annualized Gross Profit for the quarter that ended in Mar. 2025 was kr0.00 Mil. Modus Therapeutics Holding AB's average Total Assets over the quarter that ended in Mar. 2025 was kr5.53 Mil. Therefore, Modus Therapeutics Holding AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 0.00%.


Modus Therapeutics Holding AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Modus Therapeutics Holding AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Gross-Profit-to-Asset % Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - - - -

Modus Therapeutics Holding AB Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Modus Therapeutics Holding AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Modus Therapeutics Holding AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modus Therapeutics Holding AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Modus Therapeutics Holding AB's Gross-Profit-to-Asset % falls into.


;
;

Modus Therapeutics Holding AB Gross-Profit-to-Asset % Calculation

Modus Therapeutics Holding AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (20.041+4.884)/ 2 )
=0/12.4625
=0.00 %

Modus Therapeutics Holding AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=0/( (4.884+6.166)/ 2 )
=0/5.525
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Modus Therapeutics Holding AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Modus Therapeutics Holding AB Business Description

Traded in Other Exchanges
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines